# US 2023/0405128 A1 · Method for bowel preparation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0405128 A1 - Document ID: US20230405128A1 - Status: Published application - Kind: A1 - Application number: 18/455,930 - Filed: 2023-08-25 - Published: 2023-12-21 - Earliest claimed: 2011-12-07 - Assignees: MSM Innovations, Inc. - Applicants: MSM Innovations, Inc. - Inventors: Steven GORELICK; Michael SCHIFFMAN; Melody OLMSTEAD; Adam GORELICK - Web page: https://patentgrep.com/patent/US20230405128A1 ## CPC - A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof - A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides - A61K 33/42: Phosphorus; Compounds thereof - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/10: Laxatives - A61K 47/02: Inorganic compounds - A61K 47/12: Carboxylic acids; Salts or anhydrides thereof - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty. ## Claims ### Claim 1 A method for reducing a salty taste of a liquid composition for a subject, the method comprising the steps of: (a) determining the pH of the liquid composition which has a salty taste, wherein the pH ranges from about 1 to about 6.9 or is adjusted to range from about 1 to about 6.9; (b) providing a taste-modifying substance to the subject; and (c) administering orally the liquid composition to the subject after or when the taste-modifying substance is provided to the subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the liquid composition is a gastrointestinal tract preparation composition to cleanse the gastrointestinal tract of the subject. ### Claim 3 (depends on 2) The method of claim 2, wherein the gastrointestinal tract is the intestine and the gastrointestinal tract preparation composition is a bowel preparation solution. ### Claim 4 (depends on 2) The method of claim 2, wherein the gastrointestinal tract is cleansed prior to carrying out a diagnostic, therapeutic and/or surgical procedure on the patient. ### Claim 5 (depends on 2) The method of claim 2, wherein the gastrointestinal tract is cleansed prior to an endoscopy. ### Claim 6 (depends on 5) The method of claim 5, wherein the endoscopy is a colonoscopy or sigmoidoscopy. ### Claim 7 (depends on 2) The method of claim 2, wherein the gastrointestinal tract is cleansed prior to a barium enema examination, capsule endoscopy, virtual colonoscopy, colon surgery or gastrointestinal tract surgery. ### Claim 8 (depends on 1) The method of claim 1, wherein the taste-modifying substance is miraculin. ### Claim 9 (depends on 8) The method of claim 8, wherein miraculin comprises miraculin fruit, flesh of miraculin fruit, miracle fruit granules, miracle berry, miracle berry extracts, miraculin fruit tablets, miraculin berry tablets, or miraculin produced by a genetically modified organism. ### Claim 10 (depends on 1) The method of claim 1, wherein the taste-modifying substance is selected from the group consisting of thaumatin, monellin, mabinlin, brazzein, pentadin, curculin, neuculin, miraculin and mixtures thereof. ### Claim 11 (depends on 1) The method of claim 1, wherein the taste-modifying substance is provided in the form of a capsule, a tablet, a pill, granules, powders, a pellet. a solids mixture, a solution, a dispersion, an emulsion, a paste, an extract, or an isolate from a natural source. ### Claim 12 (depends on 1) The method of claim 1, wherein the taste-modifying substance is provided to the subject from about 1 minute to about 1 hour before the liquid composition is administered. ### Claim 13 (depends on 1) The method of claim 1, wherein the salty taste of the liquid composition is reduced by at least about 20% compared to the salty taste of the liquid composition had the taste-modifying substance not been provided. ### Claim 14 (depends on 1) The method of claim 1, wherein the pH ranges from about 3 to about 6.4. ### Claim 15 (depends on 1) The method of claim 1, wherein the pH ranges from about 4 to about 6.4. ### Claim 16 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition comprises a potassium salt, a sodium salt, a calcium salt, an ammonium salt or mixtures thereof. ### Claim 17 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition comprises at least one sodium phosphate. ### Claim 18 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition comprises sodium chloride, potassium chloride, and sodium bicarbonate (sodium hydrogen carbonate), sodium sulfate or mixtures thereof. ### Claim 19 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition comprises at least one alkali metal salt, and/or at least one alkaline earth metal salt. ### Claim 20 (depends on 19) The method of claim 19, wherein the alkali metal is sodium or potassium. ### Claim 21 (depends on 19) The method of claim 19, wherein the alkaline earth metal is magnesium or calcium. ### Claim 22 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition is a solution, and wherein the volume of the gastrointestinal tract preparation composition ranges from about 0. 1 liters to about 5 liters. ### Claim 23 (depends on 2) The method of claim 2, wherein the gastrointestinal tract preparation composition comprises polyethylene glycol (PEG).